Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug:182:106323.
doi: 10.1016/j.phrs.2022.106323. Epub 2022 Jun 22.

BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy

Letizia Porcelli  1 , Roberta Di Fonte  1 , Ciro L Pierri  2 , Livia Fucci  1 , Concetta Saponaro  1 , Andrea Armenio  1 , Simona Serratì  1 , Sabino Strippoli  1 , Rossella Fasano  1 , Mariateresa Volpicella  2 , Rossana Daprile  1 , Stefania Tommasi  1 , Cosmo M Ressa  1 , Michele Guida  1 , Amalia Azzariti  3
Affiliations
Free article

BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy

Letizia Porcelli et al. Pharmacol Res. 2022 Aug.
Free article

Abstract

The V600E mutation in BRAF is associated with increased phosphorylation of Erk1/2 and high sensitivity to BRAFi/MEKi combination in metastatic melanoma. In very few patients, a tandem mutation in BRAF, V600 and K601, causes a different response to BRAFi/MEKi combination. BRAFV600E;K601Q patient-derived organoids (PDOs) were generated to investigate targeted therapy efficacy and docking analysis was used to assess BRAFV600E;K601Q interactions with Vemurafenib. PDOs were not sensitive to Vemurafenib and Cobimetinib given alone and sensitive to their combination, although not as responsive as BRAFV600E PDOs. The docking analysis justified such a result showing that the tandem mutation in BRAF reduced the affinity for Vemurafenib. Tumor analysis showed that BRAFV600E;K601Q displayed both increased phosphorylation of Erk1/2 at cytoplasmic level and activation of Notch resistance signaling. This prompted us to inhibit Notch signaling with Nirogacestat, achieving a greater antitumor response and providing PDOs-based evaluation of treatment efficacy in such rare metastatic melanoma.

Keywords: Cobimetinib (PubChem CID: 16222096); Metastatic melanoma; Nirogacestat (PubChem CID: 46224413); Vemurafenib (PubChem CID: 42611257).

PubMed Disclaimer

Publication types